- 专利标题: NOVEL REPLICASE CYCLING REACTION (RCR)
-
申请号: US17930292申请日: 2022-09-07
-
公开(公告)号: US20230099592A1公开(公告)日: 2023-03-30
- 发明人: Shi-Lung LIN , Sam Lin , Chun-Hung Lin
- 申请人: Shi-Lung LIN , Sam Lin , Chun-Hung Lin
- 申请人地址: US CA Arcadia; US CA Arcadia; TW Taipei
- 专利权人: Shi-Lung LIN,Sam Lin,Chun-Hung Lin
- 当前专利权人: Shi-Lung LIN,Sam Lin,Chun-Hung Lin
- 当前专利权人地址: US CA Arcadia; US CA Arcadia; TW Taipei
- 主分类号: C12N15/10
- IPC分类号: C12N15/10 ; A61P31/12
摘要:
This invention relates to a novel composition and method for RNA/mRNA production as well as amplification using viral RNA replicase and/or RNA-dependent RNA polymerase (RdRp) enzymes and the use of associated RNA/mRNA products thereof. The present invention can be used for manufacturing and amplifying all varieties of RNA/mRNA sequences carrying at least a replicase/RdRp-binding site in the 5′- or 3′-end, or both. The RNA/mRNA so obtained is useful for not only producing mRNA vaccines and/or RNA-based medicines but for generating the mRNA-associated proteins, peptides, and/or antibodies under an in-vitro as well as in-cell translation condition. Principally, the present invention is a novel RNA replicase/RdRp-mediated RNA/mRNA amplification method, namely Replicase Cycling Reaction (RCR). The RNA replicases involved in RCR include but not limited to viral and/or bacteriophage RNA-dependent RNA polymerases (RdRp) in either modified or non-modified mRNA and/or protein compositions, particularly coronaviral (e.g. COVID-19) and hepatitis C viral (HCV) RdRp enzymes.
信息查询
IPC分类: